90Y-Pemtumomab

N/A

Report date: 2025/11/18 17:45:20

Base Information

Drug Name90Y-Pemtumomab
Drug Alias NameMonoclonal antibody HMFG1 yttrium 90 labelledYttrium 90 labelled monoclonal antibody HMFG1Theragyn90Y-muHMFG190Y-R-1549
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody murineRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Yttrium > 90Y +[5] 
Mechanisms of ActionImmunomodulatorsIonising radiation emittersAnti-MUC1
TargetsMucin-1
Therapy Area/IndicationsOvarian NeoplasmsStomach NeoplasmsAbdominal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCancer Research UK
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAntisomaF. Hoffmann-La Roche LtdNational Cancer Institute +[4] 
Active IndicationsN/A
Inactive IndicationsOvarian NeoplasmsStomach NeoplasmsAbdominal Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A